ArticleCancers2025

Effect of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor on Resistance to a CDK4/6 Inhibitor and Endocrine Therapy in ER

Satoshi Kawano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.